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Because of the recent terrorist attacks in the United States
there has been an increasing need for health care practitioners to have
a fundamental knowledge in the agents of bioterrorism.  Unlike tradi-
tional acts of overt terrorism, bioterrorism is covert.  This means the
effects of the attack will first be identified in the emergency depart-
ment.  This new threat, as evidenced by the recent exposures to
anthrax, has illustrated the importance of physicians in diagnosing,
treating, and educating patients on bioterrorism.  The goal of this
article is to set a framework for understanding the most important
agents as designated by the CDC.
The CDC has categorized the many agents of bioterrorism into
categories A, B, and C.  The A agents are felt to be the easiest to
disseminate, cause the highest mortality, and require special prepared-
ness.  B agents are felt to be second in priority, and C agents are
emerging pathogens.1  Category A agents include: smallpox, anthrax,
botulism, tularemia, and viral hemorrhagic fever.  Category B agents
include: Q fever, brucellosis, glanders, alphivirus, and various food
and waterborn pathogens. Category C agents are considered emerging
and include: nipah virus, hantavirus, tick borne hemorrhagic fever,
yellow fever, and multidrug resistant TB.  The focus of this article is
to review the various aspects of category A agents deemed important
for the recognition of a bioterrorist threat.
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Smallpox was once considered extinct and captured in a re-
pository at the CDC and the Russian equivalent in Siberia.  Kanatjan
Alibekov (Ken Alibek), once a leading bioweaponer of the Soviet
Union, defected in 1992 and stated that there were 20 tons of liquid
small pox loaded in war heads pointed at US cities.2  The concern is
that with the fall of the Russian economy this stockpile would be
open to the highest bidder.  This concern has prompted the US gov-
ernment to launch an effort to produce small pox vaccine. Tommy
Thompson, the government’s Director of Health and Human Ser-
vices, has stated publicly recently that there are currently 15.4 million
doses of vaccine now, and hopefully 300 million doses will be ready
by the end of 2002.
This poxivirus, a DNA virus also known as variola major is
highly infectious.  In 1796 Edward Jenner noted that cowpox could be
used to vaccinate people from smallpox.  The pathology of the dis-
ease has shown us it has a long incubation period.3  After being ex-
posed the virus incubates for up to 14 days.  At the end of this
incubation period the initial symptoms appear like the flu: fever,
myalgia, and back pain.  Within four days the pox rash appears on the
face and travels from head to toe.  There is a 30% case fatality that
usually results from circulating immune complexes and secondary
infection.
The disease is very infectious and spreads person-to-person,
as well as with fomites.  Should an outbreak be recognized we would
expect a large quarantine with vaccination for those within the quaran-
tine area.4  The obvious risk is the ease in which smallpox could be
delivered, and the large susceptibility to our population.
Anthrax has been weaponized for over 70 years. It is a large
gram-positive rod that forms spores. The spores are hearty and can
exist for up to 60 days in a fertile environment before converting to a
vegetative (active) form. The bacteria carries two plasmids.5  One
encodes a capsule that prevents phagocytosis.  The other plasmid
encodes three proteins: a binding protein (protective antigen) that
allows the two other proteins to enter susceptible cells (this is the
target for the vaccine).  The other two proteins are the lethal factor
and the edema factor. Using the binding proteins these weapons enter
macrophages and wreak havoc.  The edema factor is an adenylate
cyclase that disrupts water hemostasis.  The lethal factor causes the
cell to release secondary mediators of sepsis.
Although anthrax can infect the skin or GI tract, the pulmonary
form is the bioterrorist threat. Traditionally known as wool sorters
disease, this manifestation occurs when the victim breathes spores in
the size range of 1-2 um with an ld50 of about 8000 spores.8  The
mean time from exposure to symptoms is about one week.  Clinically
pulmonary anthrax has two stages:  initially flu symptoms for hours
to days, then abrupt onset of fever and sepsis.  The classic x-ray
shows a widened mediastinum although effusions are also noted.
The CDC recommends cipro 500mg po bid, 15 mg/kg for chil-
dren for 60 days.7   Recovery is possible if the toxin burden is not too
high.  In monkeys exposed to aerosol concomonent use of vaccine
with cipro has proven beneficial.  There has recently been concern
over a strain of anthrax that has a plasmid from Bacillis Cerus that has
a different binding protein and escapes the vaccine.8  There is no
person-to-person transmission so masks are not required.
Plague is the disease caused by Yersinia pestis.  Known as the
Black Death that killed 20 million people in Europe.  It is a zoonotic
disease caused by the rat flea.  As the flea is infected it develops an
ileus.  The flea bites and vomits in the rat.  As large numbers of rats die
they look for secondary hosts (humans).9  The bite of an infected flea
will cause bubonic plague.  Small numbers of bubonic plague victims
will become septic and develop pneumonic plague.
It is pneumonic plague that would be the terrorist threat.  Until
recently it was possible to buy pneumonic plague over the internet.
The Bagwan Rajneesh, an Oregon cult that poisoned salad bars with
salmonella had a supply in their germ lab.9,10  The bacteria could be
dropped as an aerosol or infected fleas could be dropped as was done
during World War II by the Japanese Unit 731 in Manchuria, China.11
The bacteria are ingested by macrophages and resist destruction. They
cause a sepsis type syndrome.  The appearance of previous healthy
people with severe pneumonic consolidation and DIC is classic.  Oc-
casionally victims will also have a cervical bubo.
The vaccine was discontinued in 1999 because it only pre-
vented bubonic plague.  Our only defense is a quick diagnosis and
therapy.  The recommended therapy is streptomycin 1 gm IM bid (15
mg/kg).11  The fatality rate is increased if therapy is started 24 hours
after treatment. Because streptomycin is infrequently used in the United
States gentamycin, doxycycline, and fluroquinolones are recommended
as alternatives.  All close contacts (within two meters) require post
exposure prophylaxis, which consists of two weeks of doxycycline.
Botulism is a disease characterized by an acute afebrile sym-
metric descending paralysis that always begins in the bulbar muscula-
ture.  The botulism toxin is secreted by the anaerobic bacteria clostridium
botulinum and is one of the most lethal toxins known to man.  One
gram of crystalline toxin evenly dispersed could kill one million people.12
Historically, the toxin has been used by the Japanese war unit during
World War II.  The germ warfare unit at Fort Detrick Maryland had
refined the process of mass producing the toxin.13  It is currently
believed that Iraq has enough toxins to kill everyone on the earth many
times over.  United Nations weapons inspectors found botulism along
with anthrax and aflatoxin in the heads of many Iraqi missiles after the
Gulf War.
Each colony of clostridum botulinum can form one of six toxin
types (A-F).  Each toxin is antigenically different but work via the
same mechanism.  The toxin enters the neuromuscular junction and
gets taken up by the presynaptic neuron.  The toxin breaks down the
apparatus that brings the acetylcholine filled vesicle to the exit point
of the neuron.  Thus, no neurotransmitter is released into the neuro-
muscular junction.
The paralysis is descending and can rapidly lead to respiratory
arrest.  Since the paralysis is descending it allows us to differentiate it
from tick paralysis and Gullian Barre syndrome.14  Currently, the only
therapy is antitoxin.  The antitoxin is antigen specific.  Until recently
only antitoxin for the most common types was available (A, B and E).
An experimental heptavalent antitoxin (A-G) will soon be available.12
Tularemia was first described in 1911 as a plague-like illness
in rodents.15  It is named after Tulare, California where it was discov-
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enter the body via skin, GI or mucosa.  It is a facultative intracellular
organism that exists in the macrophage.  The major target organs are
the spleen, lungs, liver, and kidney.  Granulomas form in these organs
with central caseating necrosis, similar to Tuberculosis.  The disease is
endemic in animals and spread by ticks, mosquitoes, lice, flies, and
ingestion of rodent excreta contaminated food.  Backpackers in the
high Sierra can acquire it from biting flies.  Humans are accidental dead
end hosts; there is no human-to-human transmission.  The disease can
have cutaneous ulceroglandular manifestations but aerosol inhalation
causes the largest morbidity and mortality.
It has been suggested that it was used as a biological weapon
during World War II on the Eastern Front.15  The potential for use as
a biological weapon was recognized by the United States and studied
extensively at Fort Detrick.13  As an aerosol in a biologic attack, we
would see nonspecific febrile illness three to five days after exposure.
Young people who have a common geographic factor and seem to have
community acquired pneumonia with a high morbidity are suspicious
for francisella tularensis.  The earliest radiographic findings include
peribronchial infiltrates advancing to bronchopneumonia in one or
more lobes.
A live attenuated vaccine has been used for laboratory workers
for years.  Unfortunately, Tularemia, unlike smallpox and anthrax, has
a very short incubation period, which makes post exposure vaccina-
tion less helpful.  The preferred therapy is similar to plague with
streptomycin as first line followed by gentamycin and doxycycline.15
Close contacts are not recommended to receive antibiotics unless they
entered a known contaminated area.  Respiratory isolation is not rec-
ommended for Tularemia patients.
Viral Hemorrhagic Fever
The Viral Hemorrhagic fever is a clinical syndrome that results
in profound internal bleeding.  Several zoonotic viruses including
filoviruses (Ebola and Marburg virus), Arenavirus family (Lassa virus
and Argentine Hemorrhagic fever), bunyavirus (Hanta virus, CCF),
and the Flavivirus family (Yellow fever and Denge HF).16
Humans are not the natural reservoir for any of these diseases.
However, if accidental transmission to humans occurs, person-to-
person transmission is possible.  All of these diseases except Dengue
fever can be infectious by aerosol or fomite from a sick person who is
massively viremic
Not all patients who contract one of these viruses will exhibit
features of viral hemorrhagic fever; it is a balance of host factors and
viral strain.  The target organ of these viruses is the vascular bed of
various organs, thus the dominant features of the illness will be a
consequence of vascular damage and permeability, i.e. rising liver func-
tion tests, proteinuria, leucopenia, and thrombocytopenia.  The syn-
drome should be suspected in any individual who traveled to an infec-
tious zone with evidence of vascular involvement, i.e. subnormal blood
pressure, postural hypotension, petechiae, non-dependent edema, or
flushed face.
Ebola is the one virus that has received the most press.  Mem-
bers of the Aum Shinrikyo cult that released serine gas in the Tokyo
Subway attempted to fly to Zaire to acquire and weaponize the vi-
rus.4  The reservoir is unknown, but believed to reside in bats.  The
symptoms begin within a few days of exposure and include fever
headache, myalgia, diarrhea and a nonspecific rash.  Within one week
this progresses to chest pain, shock, and death.  The case fatality is
extremely high making it an effective weapon.  An epidemic in the fall
of 2000 killed hundreds of persons in Uganda.  In December 2001, an
epidemic occurred in Gabon.
Marburg is in the same family as Ebola.  According to Ken
Albeck, former bioweapons engineer of USSR, this virus has been
studied, weaponized, and has killed members of the Russian military.
It has a rather sudden onset with similar symptoms to Ebola.  Five
days later a macular papular rash emerges on the trunk.  The case
fatality is believed to be less than Ebola – approximately 20%.  How-
ever, much less is known regarding the pathogensis, infectivity, and
natural history in comparison to Ebola.
Summary:  In these changing times of health care, it is easy to
overlook many of these diseases.  Developing nations see biologic
weapons as an inexpensive way to become a global power.  Many of
these agents and some of the CDC B agents can be acquired not only
by foreign terrorists, but domestic terrorists as well.  Whatever the
source of these microscopic killing machines one thing stands clear:
health care practitioners, and most notably, Emergency Department
physicians, will be at the forefront of the crisis.
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